Reviva Pharmaceuticals Net Income vs. Short Ratio
| RVPH Stock | USD 1.24 0.10 8.77% |
Net Loss | First Reported 2018-09-30 | Previous Quarter -7.9 M | Current Value -8.4 M | Quarterly Volatility 4 M |
For Reviva Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Reviva Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Reviva Pharmaceuticals Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Reviva Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Reviva Pharmaceuticals Holdings over time as well as its relative position and ranking within its peers.
Reviva |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Reviva Pharmaceuticals Short Ratio vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Reviva Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reviva Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Reviva Pharmaceuticals Holdings is rated below average in net income category among its peers. It is rated second in short ratio category among its peers . The last year's value of Net Loss was reported at (39.26 Trillion). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Reviva Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Reviva Short Ratio vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Reviva Pharmaceuticals |
| = | (39.26 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Reviva Pharmaceuticals |
| = | 19.04 X |
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
Reviva Short Ratio Comparison
Reviva Pharmaceuticals is currently under evaluation in short ratio category among its peers.
Reviva Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Reviva Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Reviva Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Reviva Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Reviva Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -49.1 M | -51.5 M | |
| Net Loss | -21.9 M | -20.8 M | |
| Income Tax Expense | -16.9 B | -16.1 B | |
| Net Interest Income | 499 K | 523.9 K | |
| Interest Income | 499 K | 523.9 K | |
| Operating Income | -39.5 T | -37.5 T | |
| Net Loss | -39.3 M | -37.3 M | |
| Income Before Tax | -39.2 M | -37.3 M | |
| Total Other Income Expense Net | 39.5 T | 41.5 T | |
| Net Loss | -39.3 M | -37.3 M | |
| Change To Netincome | 334.3 K | 218.1 K | |
| Net Loss | -1.6 M | -1.6 M | |
| Income Quality | 0.72 | 0.62 | |
| Net Income Per E B T | 1 M | 1.1 M |
Reviva Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Reviva Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Reviva Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Reviva Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Reviva Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Use Investing Themes to Complement your Reviva Pharmaceuticals position
In addition to having Reviva Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Military Industrial Thematic Idea Now
Military Industrial
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
To fully project Reviva Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Reviva Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Reviva Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.